Open Access
Early 5‐ HT 6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
Author(s) -
Berthoux Coralie,
Hamieh Al Mahdy,
Rogliardo Angelina,
Doucet Emilie L,
Coudert Camille,
Ango Fabrice,
Grychowska Katarzyna,
ChaumontDubel Séverine,
Zajdel Pawel,
Maldonado Rafael,
Bockaert Joël,
Marin Philippe,
Bécamel Carine
Publication year - 2020
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201910605
Subject(s) - library science , university hospital , medicine , computer science , family medicine
Abstract Cannabis abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of 5‐ HT 6 receptor‐operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of ∆9‐tetrahydrocannabinol ( THC ) to mice during adolescence induces a long‐lasting activation of mTOR in prefrontal cortex ( PFC ), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long‐term depression, as well as cognitive deficits in adulthood. All are prevented by administrating a 5‐ HT 6 receptor antagonist or rapamycin, during adolescence. In contrast, they are still present 2 weeks after the same treatments delivered at the adult stage. Collectively, these findings suggest a role of 5‐ HT 6 receptor‐operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of 5‐ HT 6 receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent cannabis abusers.